PMID- 26397238
OWN - NLM
STAT- MEDLINE
DCOM- 20160617
LR  - 20190930
IS  - 1560-2281 (Electronic)
IS  - 1083-3668 (Print)
IS  - 1083-3668 (Linking)
VI  - 20
IP  - 9
DP  - 2015
TI  - In vivo molecular imaging of colorectal cancer using quantum dots targeted to 
      vascular endothelial growth factor receptor 2 and optical coherence 
      tomography/laser-induced fluorescence dual-modality imaging.
PG  - 096015
LID - 10.1117/1.JBO.20.9.096015 [doi]
LID - 096015
AB  - Optical coherence tomography/laser induced fluorescence (OCT/LIF) dual-modality 
      imaging allows for minimally invasive, nondestructive endoscopic visualization of 
      colorectal cancer in mice. This technology enables simultaneous longitudinal 
      tracking of morphological (OCT) and biochemical (fluorescence) changes as 
      colorectal cancer develops, compared to current methods of colorectal cancer 
      screening in humans that rely on morphological changes alone. We have shown that 
      QDot655 targeted to vascular endothelial growth factor receptor 2 (QD655-VEGFR2) 
      can be applied to the colon of carcinogen-treated mice and provides significantly 
      increased contrast between the diseased and undiseased tissue with high 
      sensitivity and specificity ex vivo. QD655-VEGFR2 was used in a longitudinal in 
      vivo study to investigate the ability to correlate fluorescence signal to tumor 
      development. QD655-VEGFR2 was applied to the colon of azoxymethane (AOM-) or 
      saline-treated control mice in vivo via lavage. OCT/LIF images of the distal 
      colon were taken at five consecutive time points every three weeks after the 
      final AOM injection. Difficulties in fully flushing unbound contrast agent from 
      the colon led to variable background signal; however, a spatial correlation was 
      found between tumors identified in OCT images, and high fluorescence intensity of 
      the QD655 signal, demonstrating the ability to detect VEGFR2 expressing tumors in 
      vivo.
FAU - Carbary-Ganz, Jordan L
AU  - Carbary-Ganz JL
FAU - Welge, Weston A
AU  - Welge WA
FAU - Barton, Jennifer K
AU  - Barton JK
FAU - Utzinger, Urs
AU  - Utzinger U
LA  - eng
GR  - T32 HL007955/HL/NHLBI NIH HHS/United States
GR  - R01CA109835/CA/NCI NIH HHS/United States
GR  - T32HL007955/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Biomed Opt
JT  - Journal of biomedical optics
JID - 9605853
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
SB  - IM
MH  - Animals
MH  - Biomarkers, Tumor/metabolism
MH  - Cell Line, Tumor
MH  - Colorectal Neoplasms/*metabolism/*pathology
MH  - Image Enhancement/methods
MH  - Image Interpretation, Computer-Assisted/methods
MH  - Mice
MH  - Microscopy, Fluorescence/*methods
MH  - Molecular Imaging/*methods
MH  - Multimodal Imaging/methods
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Subtraction Technique
MH  - Tomography, Optical Coherence/*methods
MH  - Vascular Endothelial Growth Factor Receptor-2/*metabolism
PMC - PMC4963467
EDAT- 2015/09/24 06:00
MHDA- 2016/06/18 06:00
PMCR- 2016/09/23
CRDT- 2015/09/24 06:00
PHST- 2015/05/21 00:00 [received]
PHST- 2015/08/17 00:00 [accepted]
PHST- 2015/09/24 06:00 [entrez]
PHST- 2015/09/24 06:00 [pubmed]
PHST- 2016/06/18 06:00 [medline]
PHST- 2016/09/23 00:00 [pmc-release]
AID - 2444997 [pii]
AID - 150300R [pii]
AID - 10.1117/1.JBO.20.9.096015 [doi]
PST - ppublish
SO  - J Biomed Opt. 2015;20(9):096015. doi: 10.1117/1.JBO.20.9.096015.